SCHEMBL4732730

SCHEMBL4732730

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(P(C)(C)=O)cc3)cc2)ccn1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 8/20 0.71
EPHX2 P34913 4/20 0.71
KDR P35968 9/20 0.65
MAPK14 Q16539 6/20 0.65
RET P07949 4/20 0.65
SRC P12931 3/20 0.65
HIPK4 Q8NE63 3/20 0.65
ABL1 P00519 3/20 0.65
EPHA2 P29317 3/20 0.65
MAP3K20 Q9NYL2 3/20 0.65
AURKB Q96GD4 3/20 0.65
PLK4 O00444 2/20 0.65
AURKA O14965 2/20 0.65
MAPK13 O15264 2/20 0.65
MAP4K4 O95819 2/20 0.65
LCK P06239 2/20 0.65
FYN P06241 2/20 0.65
LYN P07948 2/20 0.65
RPS6KB1 P23443 2/20 0.65
AXL P30530 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257980 0.92 RAF1 (0.82) RAF1EPHX2KDRMAPK14RET
SCHEMBL1532339 0.88 RAF1 (0.77) RAF1EPHX2KDRMAPK14RET
SCHEMBL12391532 0.87 RAF1 (0.76) RAF1EPHX2KDRMAPK14RET
SCHEMBL10163311 0.87 RAF1 (0.76) RAF1EPHX2KDRMAPK14RET
SCHEMBL16620832 0.86 RAF1 (0.74) RAF1EPHX2KDRMAPK14RET
SCHEMBL28430251 0.86 RAF1 (0.78) RAF1EPHX2KDRMAPK14RET
SCHEMBL19888730 0.86 RAF1 (0.78) RAF1EPHX2KDRMAPK14RET
SCHEMBL15624828 0.83 RAF1 (1.00) RAF1EPHX2KDRMAPK14RET
SCHEMBL12500767 0.83 RAF1 (0.73) RAF1EPHX2KDRMAPK14RET
SCHEMBL16628087 0.83 KDR (0.83) RAF1EPHX2KDRMAPK14RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed
WO-2008046216-A1 KINASE INHIBITORS AND USES THEREOF METHYLGENE, INC. (CA) 2008-04-24 WO disclosed
WO-2008046216-A1 KINASE INHIBITORS AND USES THEREOF METHYLGENE, INC. (CA) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF ABL1, MAP3K20, MAP3K1 RAF1 104/4885EPHX2 2019/4885KDR 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.